[Hyperkalemia in heart failure: new solutions for an old problem]
Simona Romani1, Aldostefano Porcari1, Enrico Fabris1
1Dipartimento Cardiovascolare, Azienda Sanitaria Universitaria Integrata (ASUITS) e Università degli Studi di Trieste, Trieste.
Giornale Italiano Di Cardiologia (2006)
|October 9, 2019
Summary
Hyperkalemia, or high potassium, is common in heart failure patients and limits treatment. New drugs help manage potassium levels, allowing more effective heart failure therapies.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Potassium homeostasis is regulated by the kidneys and gastrointestinal tract.
- Heart failure patients often experience renal failure and hyperkalemia due to cardiorenal syndrome and medications like renin-angiotensin-aldosterone system inhibitors.
- The prognostic significance of hyperkalemia in heart failure remains uncertain, despite its association with cardiac conduction disorders and arrhythmias.
Purpose of the Study:
- To review the pathophysiological, epidemiological, and prognostic aspects of hyperkalemia in heart failure.
- To analyze current and emerging treatments for hyperkalemia in heart failure patients.
- To highlight how managing hyperkalemia can improve the use of essential heart failure therapies.
Main Methods:
- Literature review of pathophysiological mechanisms.
- Epidemiological data analysis regarding hyperkalemia prevalence in heart failure.
- Evaluation of treatment strategies, including novel pharmacological agents.
Main Results:
- Hyperkalemia and renal damage are significant barriers to optimizing heart failure treatments.
- New drugs offer improved prevention and management of hyperkalemia.
- These advancements facilitate the use of critical anti-neurohormonal therapies in patients previously unable to tolerate them.
Conclusions:
- Effective management of hyperkalemia is crucial for heart failure patient care.
- Novel hyperkalemia treatments expand therapeutic options for heart failure.
- Addressing hyperkalemia enables better application of guideline-directed medical therapy, improving patient outcomes.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
760
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
760
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure VI: Adjunct Therapies
223
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
223
01:30Heart Failure V: Medical Management
188
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
188
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
867
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867
01:22Heart Failure Drugs: β-Blockers
721
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
721